Clinical Trials
12 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05092451 2026-05-06
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05278208 2026-04-13
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT06937866 2025-11-21
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Indiana University
Phase 1/2 Recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT04657315 2023-01-18
MSC11FCD-GBM
CHA University
Phase 1/2 Completed
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT04648826 2021-12-17
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT00983398 2021-10-26
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
OHSU Knight Cancer Institute
Phase 1/2 Unknown
NCT01966913 2019-02-19
TAXIFIII
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Unknown
NCT00179816 2010-10-11
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Unknown
NCT00187109 2008-04-10
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
St. Jude Children's Research Hospital
Phase 1/2 Completed